Reuters logo
BRIEF-Soligenix receives FDA protocol clearance of pivotal phase 3 clinical trial of sgx942
2017年5月3日 / 上午11点14分 / 6 个月前

BRIEF-Soligenix receives FDA protocol clearance of pivotal phase 3 clinical trial of sgx942

May 3 (Reuters) - Soligenix Inc:

* Soligenix receives FDA protocol clearance of pivotal phase 3 clinical trial of sgx942 for the treatment of oral mucositis in head and neck cancer patients

* Soligenix Inc- Soligenix plans to begin the study in Q2 of 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below